With Alamar’s innovative NULISA™ technology, this long-standing challenge has finally been overcome. With the ability to deeply interrogate the proteome at attomolar sensitivity, even low-abundance proteins can now be detected.
Additionally, NULISA™ allows for the simultaneous measurement of changes in hundreds to thousands of proteins from a single sample, providing a breadth of data previously unattainable by existing technologies. This breakthrough is set to revolutionize our understanding of the human proteome and its role in health and disease.